MDCO up +3.31% percent Today $MDCO High is at 25.5

MDCO up +3.31% percent Today $MDCO High is at 25.54 and the Low 24.48 with current volume of 192,548.

Recent News posted below.

The Medicines Company MDCO other info.
http://investorshangout.com/The-Medicines-Com...DCO-54723/

MDCO The Medicines Company Recent Headline News

The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
Business Wire - Sun Nov 16, 9:30AM CST
The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association's Annual Scientific Sessions in Chicago.
MDCO: 25.35 (+0.88)

The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and Investigational Antiplatelet Agent Cangrelor at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
Business Wire - Fri Nov 14, 9:32AM CST
The Medicines Company (NASDAQ:MDCO) will present new data from studies involving the investigational lipid-modifying agent MDCO-216 and investigational intravenous antiplatelet agent cangrelor during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19. The oral presentations and abstracts involve clinical data and analyses from two core areas of cardiovascular medicine for the Company: lipid-modifying therapies and acute cardiovascular care.
MDCO: 25.35 (+0.88)

The Medicines Company to Participate in Credit Suisse Healthcare Conference
Business Wire - Tue Nov 11, 10:07AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 12th at 1:00 PM Mountain Time / 3:00 PM Eastern Time.
MDCO: 25.35 (+0.88)

Health Economic Data on The Medicines Company's Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Business Wire - Fri Nov 07, 2:00PM CST
The Medicines Company (NASDAQ:MDCO) today announced that data from two health economics analyses will be presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) being held in Amsterdam, November 8-12. The abstracts involve analyses from two core areas of hospital focus for The Medicines Company: serious infectious disease care and acute cardiovascular care.
MDCO: 25.35 (+0.88)

Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST

ALNY: 89.54 (-0.58), MDCO: 25.35 (+0.88), SNY: 47.32 (+0.64)

The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE(TM) in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria
Business Wire - Wed Nov 05, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE(TM) (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of serious bacterial infections due to gram-negative bacteria, particularly KPC (Klebsiella pneumoniae carbapenemase)-producing carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 25.35 (+0.88)

Update to The Medicines Company Investor & Analyst Day on November 5
Business Wire - Tue Nov 04, 3:33PM CST
As previously announced, The Medicines Company (NASDAQ:MDCO) will host an Investor & Analyst Day on Wednesday, November 5, 2014 at the Roosevelt Hotel in New York. The Investor and Analyst Day presentations will start at 8:25 am and go to 12:30 pm Eastern Time. Breakfast will be served from 8:00 am to 8:25 am. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.35 (+0.88)

The Medicines Company to Webcast Investor & Analyst Day on November 5
Business Wire - Thu Oct 30, 3:03PM CDT
The Medicines Company (NASDAQ: MDCO) has scheduled a webcast of its upcoming Investor & Analyst Day on Wednesday, November 5, 2014, from 8:00 am to 12:00 pm Eastern Time. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.35 (+0.88)

Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 303.97 (-1.46), CBST: 72.65 (+2.13), MDCO: 25.35 (+0.88), SRPT: 15.21 (-0.11), ALXN: 187.39 (-1.37), AMGN: 158.67 (+0.99), CELG: 104.62 (+0.57)

The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 107.54 (+0.64), BIIB: 303.97 (-1.46), MDCO: 25.35 (+0.88), ILMN: 182.03 (+1.53)

The Medicines Co.'s Angiomax Gets Favorable Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:31PM CDT
The Medicines Co. (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan.
IPXL: 28.80 (-0.06), ACT: 248.77 (+5.00), MDCO: 25.35 (+0.88), MYL: 55.41 (+1.36)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.84 (+0.04), AMKR: 6.76 (+0.37), VTAE: 17.02 (+0.66), ASTI: 1.92 (-0.08), CLF: 10.42 (-0.27), LMNX: 18.29 (-0.09), IDTI: 17.25 (-0.44), HNR: 2.86 (-0.13), VDSI: 27.11 (+0.15), DCO: 23.88 (-0.26), MDCO: 25.35 (+0.88), SCYX: 9.40 (-0.09), VGGL: 3.74 (+0.63), RCPT: 104.46 (-2.09), IBIO: 1.09 (+0.04), SNY: 47.32 (+0.64), TWTR: 40.64 (-1.21), DPW: 1.66 (-0.04), MERU: 3.71 (-0.07), SANM: 24.88 (-0.24)

The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA(TM) (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons
Business Wire - Tue Oct 28, 10:30AM CDT
The Medicines Company (NASDAQ: MDCO) today announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA(TM) (fibrin sealant), formerly known as Fibrocaps, at the 100th Clinical Congress of the American College of Surgeons in San Francisco, CA. As previously reported, the Phase III trial, FINISH-3, which studied a total of 719 patients, met all primary and secondary hemostasis efficacy endpoints in four distinct surgical indications of spinal surgery, hepatic resection, vascular surgery and soft tissue dissection. RAPLIXA, currently under regulatory review with the U.S. Food and Drug Administration and the European Medicines Agency, is a dry powder topical formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery.
MDCO: 25.35 (+0.88)

Medicines Co. prevails in patent challenge from Mylan
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:43AM CDT

MDCO: 25.35 (+0.88), MYL: 55.42 (+1.37)

Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Tue Oct 28, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. ALN-PCSsc is a subcutaneously administered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Per the filed CTA, the Phase 1 trial of ALN-PCSsc will be conducted in the U.K. as a randomized, single-blind, placebo-controlled, single ascending- and multi-dose study, enrolling up to 76 volunteer subjects with elevated baseline LDL-C (greater-than or equal to 100 mg/dL). Following approval of the CTA, the companies expect to initiate dosing in the Phase 1 trial in late 2014 or early 2015, with initial data expected to be reported in mid-2015.
ALNY: 89.54 (-0.58), MDCO: 25.35 (+0.88)

The Medicines Company Wins Favorable Judgment in Angiomax(R) (Bivalirudin) Patent Litigation
Business Wire - Mon Oct 27, 7:04PM CDT
The Medicines Company (NASDAQ:MDCO) announced the U.S. District Court for the Northern District of Illinois in The Medicines Company v. Mylan, Inc. entered judgment in favor of The Medicines Company on all issues concerning U.S. Patent No. 7,582,727 (the "'727 patent" . Following a June 2014 trial, Judge Amy St. Eve found all of the asserted claims (patent claims 1-3, 7-10, and 17) are infringed by Mylan's Abbreviated New Drug Application ("ANDA" . The same claims were also found to be valid and enforceable.
MDCO: 25.35 (+0.88)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:40PM CDT

AMKR: 6.76 (+0.37), KSS: 57.63 (+0.51), WMGI: 28.07 (-0.01), MDCO: 25.35 (+0.88), AOL: 46.47 (+0.43), KN: 19.58 (-0.27), RCPT: 104.46 (-2.09), TRNX: 26.29 (-0.13), TWTR: 40.65 (-1.20), RGC: 22.42 (+0.04)

The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 12:00PM CDT
The Medicines Co. reported earnings of 5 cents per share in the third quarter of 2014, compared to the year-ago earnings of 38 cents per share.
ACT: 248.77 (+5.00), MDCO: 25.35 (+0.88), MYL: 55.42 (+1.37), HSP: 58.23 (-0.05)

The Medicines Company Announces Participation in 2014 American College of Emergency Physicians Scientific Assembly
Business Wire - Fri Oct 24, 1:54PM CDT
---Presentations Include Now Available ORBACTIV(TM) (oritavancin) and CLEVIPREX (clevidipine)
MDCO: 25.35 (+0.88)

Opposing Market Forces Lead to Limited Growth of the Acute Pain Market Through 2023
PR Newswire - Thu Oct 23, 1:00PM CDT
Decision Resources Group finds that the acute pain market will grow minimally from $12.7 billion in 2013 to $13.3 billion in 2023 across the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan), representing an annual growth rate of less than 0.5 percent. The limited sales increase expected over the 2013-2023 forecast period masks the underlying dynamics in this market. Through 2018, market growth attributable to a growing patient population and continued uptake of several branded pain therapies--most notably Mallinckrodt's Ofirmev and Pacira's Exparel in the United States and fast-acting fentanyl formulations across all markets under study--will be tempered by generic erosion of several sales-leading pain therapies, such as Pfizer/Astellas' Celebrex/Celecox. During the second half of the forecast period, the market impact of emerging therapies--such as The Medicines Company's Ionsys and AcelRx/Grunenthal's Zalviso--will be largely offset by generic entry of several pain therapies, including Ofirmev and fast-acting fentanyl products, that had been contributing notable growth to the market from 2013 to 2018.
MDCO: 25.35 (+0.88)